title: [Drug eluting stents: long term results in clinical practice. Comparison between rapamycin and paclitaxel eluting stents].
abstract: OBJECTIVE
  Drug eluting stents have demonstrated their superiority versus bare metal stents in the reduction of restenosis and major adverse cardiac events. Most studies do not identificate differences between rapamycin and paclitaxel eluting stent.
  
  
  METHODS
  Retrospective study. We identified all patients treated with rapamycin eluting stents or paclitaxel eluting stents during 2003 and 2004 in our center. We analized major adverse cardiac events incidence in the whole group and we investigated for differences between paclitaxel and rapamicin groups.
  
  
  RESULTS
  170 patients were included. 98 treated with rapamycin eluting stents and 72 with paclitaxel eluting stents. Medium follow up was 365 days. There were no differences between groups in demographic or periprocedural variables. The incidence of major adverse cardiac events was 3.5% in the entire group (2.0% in rapamycin group and 5.6% in paclitaxel group; p = 0.43).
  
  
  CONCLUSIONS
  Drug eluting stents show a low incidence of major adverse cardiac events when they are utilized in usual clinical practice. With regard to this, we have not found differences between most used devices in our environment, rapamycin eluting stents and paclitaxel eluting stents.
authors.affiliation: Servicio de Cardiología, Hospital Universitario Miguel Servet, Zaragoza, España. juansrl@hotmail.com
authors.forename: Juan
authors.initials: J
authors.lastname: Sánchez-Rubio Lezcano
authors.forename: José Gabriel
authors.initials: JG
authors.lastname: Galache Osuna
authors.forename: Isabel
authors.initials: I
authors.lastname: Calvo Cebollero
authors.forename: Antonela
authors.initials: A
authors.lastname: Lukic
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Diarte de Miguel
authors.forename: Luis Javier
authors.initials: LJ
authors.lastname: Placer Peralta
mesh_terms: D003131:Combined Modality Therapy; D023921:Coronary Stenosis / Q000628:therapy*; D016503:Drug Delivery Systems / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage*; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000009:adverse effects; D013997:Time Factors
chemical_list: D017239:Paclitaxel; D020123:Sirolimus